Fig. 1From: Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2a LigandTracer curve representing 177Lu-AbN44v6 uptake and retention of HCT116 (black) and UM-SCC-74B (gray). b Specificity evaluation of 177Lu-AbN44v6 using HCT116 and UM-SCC-74B. p < 0.0001 (****), n ≥ 3, error bars presented as SDBack to article page